BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECVAYLI (teclistamab-cqyv) is a bispecific T-cell engaging antibody that bridges CD3 on T-cells to BCMA on multiple myeloma cells, redirecting immune attack. It is approved for relapsed/refractory multiple myeloma in combination with daratumumab and standard backbone therapy. The mechanism activates T-cells and drives lysis of myeloma cells through dual-target engagement.
$0.29MPart D
PeakProduct is in peak commercial phase with moderate uptake; brand team likely scaling but facing competitive pressure in the bispecific myeloma space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECVAYLI offers exposure to a high-impact oncology franchise at peak commercial momentum, with opportunities in specialty pharma sales, payer negotiations, and clinical trial management. However, the low linked job count (0) suggests limited active hiring, indicating roles are either newly created, internally filled, or not yet indexed in job tracking systems.
Brand Manager
Worked on TECVAYLI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.